Abstract

Genome-wide association studies (GWAS) of chronic lymphocytic leukemia (CLL) have shown that common genetic variation contributes to the heritable risk of CLL. To identify additional CLL susceptibility loci, we conducted a GWAS and performed a meta-analysis with a published GWAS totaling 1,739 individuals with CLL (cases) and 5,199 controls with validation in an additional 1,144 cases and 3,151 controls. A combined analysis identified new susceptibility loci mapping to 3q26.2 (rs10936599, P = 1.74 × 10−9), 4q26 (rs6858698, P = 3.07 × 10−9), 6q25.2 (IPCEF1, rs2236256, P = 1.50 × 10−10) and 7q31.33 (POT1, rs17246404, P = 3.40 × 10−8). Additionally, we identified a promising association at 5p15.33 (CLPTM1L, rs31490, P = 1.72 × 10−7) and validated recently reported putative associations at 5p15.33 (TERT, rs10069690, P = 1.12 × 10−10) and 8q22.3 (rs2511714, P = 2.90 × 10−9). These findings provide further insights into the genetic and biological basis of inherited genetic susceptibility to CLL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 103, 4389–4395 (2004).

  2. 2.

    , , , & Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 94, 647–653 (2009).

  3. 3.

    et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).

  4. 4.

    et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132–136 (2010).

  5. 5.

    et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood 120, 843–846 (2012).

  6. 6.

    et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).

  7. 7.

    & Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28, 817–825 (2010).

  8. 8.

    et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat. Genet. 42, 973–977 (2010).

  9. 9.

    et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221–1225 (2013).

  10. 10.

    et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 61, 248–254 (2012).

  11. 11.

    et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat. Genet. 45, 422–427 (2013).

  12. 12.

    , & Negative feedback regulation of antigen receptors through calmodulin inhibition of E2A. J. Immunol. 188, 6175–6183 (2012).

  13. 13.

    et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45, 526–530 (2013).

  14. 14.

    et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42, 224–228 (2010).

  15. 15.

    et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 43, 1108–1113 (2011).

  16. 16.

    et al. New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41, 909–914 (2009).

  17. 17.

    et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40, 1407–1409 (2008).

  18. 18.

    et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978–984 (2010).

  19. 19.

    et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371–384 (2013).

  20. 20.

    et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nat. Genet. 43, 1210–1214 (2011).

  21. 21.

    et al. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4. Hum. Mol. Genet. 22, 3373–3380 (2013).

  22. 22.

    , , , & Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999).

  23. 23.

    et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084–1089 (2012).

  24. 24.

    , , & Common genetic variation contributes significantly to the risk of developing chronic lymphocytic leukemia. Haematologica 98, e23–e24 (2013).

  25. 25.

    et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC Press, Lyon, France, 2008).

  26. 26.

    et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370, 230–239 (2007).

  27. 27.

    & Cohort profile: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34–41 (2006).

  28. 28.

    et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305–1309 (2007).

  29. 29.

    , & Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC Cancer 8, 244 (2008).

  30. 30.

    et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J. Natl. Cancer Inst. 97, 199–209 (2005).

  31. 31.

    et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257–2317 (2003).

  32. 32.

    et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21, 201–206 (2007).

  33. 33.

    Telomere measurement by quantitative PCR. Nucleic Acids Res. 30, e47 (2002).

  34. 34.

    , , , & hTERT (–1327)T/C polymorphism is not associated with age-related telomere attrition in peripheral blood. Biochem. Biophys. Res. Commun. 358, 215–218 (2007).

  35. 35.

    et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am. J. Hematol. 88, 647–651 (2013).

  36. 36.

    et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).

  37. 37.

    et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243–1246 (2005).

  38. 38.

    Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis (Oxford University Press, 1994).

  39. 39.

    & Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).

  40. 40.

    , , , & A fine-scale map of recombination rates and hotspots across the human genome. Science 310, 321–324 (2005).

  41. 41.

    et al. The structure of haplotype blocks in the human genome. Science 296, 2225–2229 (2002).

  42. 42.

    & HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930–D934 (2012).

  43. 43.

    et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790–1797 (2012).

  44. 44.

    et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 15, 901–913 (2005).

  45. 45.

    et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26, 2474–2476 (2010).

Download references

Acknowledgements

Leukaemia and Lymphoma Research provided principal funding for the study (LRF05001 and LRF06002). We acknowledge support from Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the Arbib Fund. We also acknowledge National Health Service funding to the Royal Marsden/Institute of Cancer Research; National Institute for Health Research Biomedical Research Centre. The study made use of genotyping data on the 1958 Birth Cohort; a full list of the investigators who contributed to the generation of these data is available at http://www.wtccc.org.uk/. We thank L. Padyukov (Karolinska Institutet) and the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) group for providing control samples from the Swedish population for the Swedish replication study. We are grateful to all clinicians for their involvement in patient ascertainment. This study makes use of data generated by the Wellcome Trust Case-Control Consortium 1 and 2. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk/. We are grateful to all investigators and all the patients and individuals for their participation. We also thank the clinicians, other hospital staff and study staff that contributed to the blood sample and data collection for this study.

Author information

Author notes

    • Helen E Speedy
    •  & Maria Chiara Di Bernardo

    These authors contributed equally to this work.

Affiliations

  1. Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.

    • Helen E Speedy
    • , Maria Chiara Di Bernardo
    • , Georgina P Sava
    • , Amy Holroyd
    • , Yufei Wang
    •  & Richard S Houlston
  2. Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.

    • Martin J S Dyer
  3. Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

    • Nicola J Sunter
    • , Andrew G Hall
    •  & James M Allan
  4. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

    • Larry Mansouri
    •  & Richard Rosenquist
  5. Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Hematology and Transplantation, Lund University, Lund, Sweden.

    • Gunnar Juliusson
  6. Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

    • Karin E Smedby
  7. Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.

    • Göran Roos
  8. Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.

    • Sandrine Jayne
    •  & Aneela Majid
  9. Haemato-Oncology, Division of Molecular Pathology, Institute of Cancer Research, Sutton, Surrey, UK.

    • Claire Dearden
    •  & Daniel Catovsky
  10. Haematological Sciences, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.

    • Tryfonia Mainou-Fowler
  11. Department of Haematology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

    • Graham H Jackson
  12. Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle-upon-Tyne, UK.

    • Geoffrey Summerfield
  13. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

    • Robert J Harris
    •  & Andrew R Pettitt
  14. Department of Haematology, Hull Royal Infirmary, Hull, UK.

    • David J Allsup
  15. Hull York Medical School and University of Hull, Hull, UK.

    • James R Bailey
  16. Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.

    • Guy Pratt
  17. Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.

    • Chris Pepper
  18. Cardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.

    • Chris Fegan

Authors

  1. Search for Helen E Speedy in:

  2. Search for Maria Chiara Di Bernardo in:

  3. Search for Georgina P Sava in:

  4. Search for Martin J S Dyer in:

  5. Search for Amy Holroyd in:

  6. Search for Yufei Wang in:

  7. Search for Nicola J Sunter in:

  8. Search for Larry Mansouri in:

  9. Search for Gunnar Juliusson in:

  10. Search for Karin E Smedby in:

  11. Search for Göran Roos in:

  12. Search for Sandrine Jayne in:

  13. Search for Aneela Majid in:

  14. Search for Claire Dearden in:

  15. Search for Andrew G Hall in:

  16. Search for Tryfonia Mainou-Fowler in:

  17. Search for Graham H Jackson in:

  18. Search for Geoffrey Summerfield in:

  19. Search for Robert J Harris in:

  20. Search for Andrew R Pettitt in:

  21. Search for David J Allsup in:

  22. Search for James R Bailey in:

  23. Search for Guy Pratt in:

  24. Search for Chris Pepper in:

  25. Search for Chris Fegan in:

  26. Search for Richard Rosenquist in:

  27. Search for Daniel Catovsky in:

  28. Search for James M Allan in:

  29. Search for Richard S Houlston in:

Contributions

R.S.H. obtained financial support, designed the project and provided overall project management. R.S.H. drafted the manuscript. H.E.S. performed project management and supervised genotyping. M.C.D.B. performed bioinformatic and statistical analyses. G.P.S. and A.H. performed genotyping. Y.W. and M.C.D.B. performed imputation analysis. D.C. and R.S.H. established the International CLL Linkage Consortium (ICLLLC). C.D. and D.C. performed recruitment of samples. In Sweden, L.M. performed sample collection and prepared DNA; R.R. performed collection of all cases and G.J. and K.E.S. performed sample collection in the Scandinavian Lymphoma Etiology (SCALE) study; and G.R. performed telomere analysis. In Newcastle, J.M.A. and D.J.A. conceived of the NCLLC; J.M.A. obtained financial support, supervised laboratory management and oversaw genotyping of cases with NCLLC; N.J.S. performed sample management of cases; A.G.H. developed the Newcastle Haematology Biobank, incorporating NCLLC; and T.M.-F., G.H.J., G.S., R.J.H., A.R.P., D.J.A., J.R.B., G.P., C.P. and C.F. developed protocols for recruitment of individuals with CLL and sample acquisition and performed sample collection of cases. In Leicester, M.J.S.D. performed overall management, collection and processing of samples; and S.J. and A.M. performed DNA extractions and IGVH mutation assays. All authors contributed to the final paper.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Richard S Houlston.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1–7 and Supplementary Figures 1–5

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.2843

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing